Cardiac amyloidosis: a changing epidemiology with open challenges

Abstract

Cardiac amyloidosis (CA) is increasingly diagnosed due to the advancements made in diagnostics and therapeutics in the last decades, particularly in the field of transthyretin-related CA. Studies that have used bone scintigraphy for screening at-risk conditions have shown that about one out of ten patients with heart failure with preserved ejection fraction (HFpEF), aortic stenosis undergoing valve replacement, or hypertrophic cardiomyopathy (HCM) diagnosed later in life might have an underlying or concomitant CA. At the same time, the epidemiology of these conditions is also rapidly evolving. HFpEF has become the leading form of heart failure, and HFpEF patients are increasingly cared for in non-cardiology settings due to their older age and substantial burden of comorbidities. Aortic stenosis is increasingly treated percutaneously at earlier stages of the disease, determining a significant gain in survival. Hypertrophic cardiomyopathy is nowadays mostly diagnosed in middle-aged adults with near-normal life expectancy, with a greater chance of misdiagnosing CA as HCM or of an overlap between the two conditions. In all these contexts, the therapeutic and prognostic implications of diagnosing CA will have to be further investigated. Meanwhile, the diagnostic workup of patients with suspected CA should always be completed with the systematic exclusion of a plasma cell dyscrasia, the acquisition of tomographic imaging at bone scintigraphy, and the completion of genetic testing for transthyretin-related forms.

Keywords

Amyloidosis / transthyretin / light chain / epidemiology / heart failure / aortic stenosis / hypertrophic cardiomyopathy / hypertrophy

References

[1] Giovanni B, Gustafson D, Adamson MB, Delgado DH. Hiding in plain sight: cardiac amyloidosis, an emerging epidemic.Can J Cardiol2020;36:373-83

[2] Garcia-Pavia P,Adler Y.Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases.Eur J Heart Fail2021;23:512-26

[3] Witteles RM.AL amyloidosis for the cardiologist and oncologist: epidemiology, diagnosis, and management.JACC CardioOncol2019;1:117-30 PMCID:PMC8352106

[4] Witteles RM,Damy T.Screening for transthyretin amyloid cardiomyopathy in everyday practice.JACC Heart Fail2019;7:709-16

[5] Lousada I,Landau H,Merlini G.Light chain amyloidosis: patient experience survey from the amyloidosis research consortium.Adv Ther2015;32:920-8 PMCID:PMC4635176

[6] Papoutsidakis N,Rodonski A.Time course of common clinical manifestations in patients with transthyretin cardiac amyloidosis: delay from symptom onset to diagnosis.J Card Fail2018;24:131-3

[7] Gillmore JD,Falk RH.Nonbiopsy diagnosis of cardiac transthyretin amyloidosis.Circulation2016;133:2404-12

[8] Maurer MS,Gundapaneni B.ATTR-ACT Study InvestigatorsTafamidis treatment for patients with transthyretin amyloid cardiomyopathy.N Engl J Med2018;379:1007-16

[9] Kyle RA,Kurtin PJ.Incidence of AL amyloidosis in Olmsted County, Minnesota, 1990 through 2015.Mayo Clin Proc2019;94:465-71 PMCID:PMC6401262

[10] Zampieri M,Del Monaco G.Changes in the perceived epidemiology of amyloidosis: 20 year-experience from a Tertiary Referral Centre in Tuscany.Int J Cardiol2021;335:123-7

[11] Tini G,Biagini E.Current patterns of beta-blocker prescription in cardiac amyloidosis: an Italian nationwide survey.ESC Heart Fail2021;8:3369-74 PMCID:PMC8318433

[12] Banypersad SM,Whelan C,Wechalekar AD.Updates in cardiac amyloidosis: a review.J Am Heart Assoc2012;1:e000364 PMCID:PMC3487372

[13] Gilstrap LG,Wang Y.Epidemiology of cardiac amyloidosis-associated heart failure hospitalizations among fee-for-service Medicare beneficiaries in the United States.Circ Heart Fail2019;12:e005407 PMCID:PMC6557425

[14] Tini G,Gemelli C,Canepa M.Amyloid cardiomyopathy in the rare transthyretin Tyr78Phe mutation.J Cardiovasc Transl Res2019;12:514-6

[15] Dungu JN,Wykes K.Afro-Caribbean heart failure in the United Kingdom: cause, outcomes, and ATTR V122I cardiac amyloidosis.Circ Heart Fail2016;9:e003352

[16] López-Sainz Á,Dominguez F.Prevalence of cardiac amyloidosis among elderly patients with systolic heart failure or conduction disorders.Amyloid2019;26:156-63

[17] Takeda M,Tachi M,Mizuno K.MRI differentiation of cardiomyopathy showing left ventricular hypertrophy and heart failure: differentiation between cardiac amyloidosis, hypertrophic cardiomyopathy, and hypertensive heart disease.Jpn J Radiol2013;31:693-700

[18] Hahn VS,Vaishnav J.Endomyocardial biopsy characterization of heart failure with preserved ejection fraction and prevalence of cardiac amyloidosis.JACC Heart Fail2020;8:712-24 PMCID:PMC7604801

[19] Connors LH,Skinner M.Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study.Circulation2016;133:282-90 PMCID:PMC4718760

[20] González-López E,Guzzo-Merello G.Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.Eur Heart J2015;36:2585-94

[21] Bennani Smires Y,Ribes D.Pilot study for left ventricular imaging phenotype of patients over 65 years old with heart failure and preserved ejection fraction: the high prevalence of amyloid cardiomyopathy.Int J Cardiovasc Imaging2016;32:1403-13

[22] Rapezzi C,Campo G.Aortic stenosis, transcatheter aortic valve replacement and transthyretin cardiac amyloidosis: are we progressively unraveling the tangle?.Eur J Heart Fail2021;23:259-63

[23] Castaño A,Hamid N.Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement.Eur Heart J2017;38:2879-87 PMCID:PMC5837725

[24] Rosenblum H,Narotsky DL.Unveiling outcomes in coexisting severe aortic stenosis and transthyretin cardiac amyloidosis.Eur J Heart Fail2021;23:250-8

[25] Nitsche C,Patel KP.Prevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosis.J Am Coll Cardiol2021;77:128-39 PMCID:PMC7805267

[26] Nitsche C,Kammerlander AA.Light-chain and transthyretin cardiac amyloidosis in severe aortic stenosis: prevalence, screening possibilities, and outcome.Eur J Heart Fail2020;22:1852-62 PMCID:PMC7687139

[27] Scully PR,Treibel TA.Prevalence and outcome of dual aortic stenosis and cardiac amyloid pathology in patients referred for transcatheter aortic valve implantation.Eur Heart J2020;41:2759-67 PMCID:PMC7395329

[28] Tini G,Benenati S.Yield of bone scintigraphy screening for transthyretin-related cardiac amyloidosis in different conditions: methodological issues and clinical implications.Eur J Clin Invest2021;51:e13665

[29] Maurizi N,Fumagalli C.Prevalence of cardiac amyloidosis among adult patients referred to tertiary centres with an initial diagnosis of hypertrophic cardiomyopathy.Int J Cardiol2020;300:191-5

[30] Cariou E,Victor G.Toulouse Amyloidosis Research Network collaborators*Diagnostic score for the detection of cardiac amyloidosis in patients with left ventricular hypertrophy and impact on prognosis.Amyloid2017;24:101-9

[31] Bozkurt B,Tsutsui H.Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association.Eur J Heart Fail2021;23:352-80

[32] Groenewegen A,Mosterd A.Epidemiology of heart failure.Eur J Heart Fail2020;22:1342-56 PMCID:PMC7540043

[33] Steinberg BA,Heidenreich PA.Get With the Guidelines Scientific Advisory Committee and InvestigatorsTrends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes.Circulation2012;126:65-75

[34] Roger VL.Epidemiology of heart failure: a contemporary perspective.Circ Res2021;128:1421-34

[35] Chamberlain AM,Gerber Y.Multimorbidity in heart failure: a community perspective.Am J Med2015;128:38-45 PMCID:PMC4282820

[36] Vaduganathan M,Michel A.Mode of death in heart failure with preserved ejection fraction.J Am Coll Cardiol2017;69:556-69

[37] Di Lenarda A,Maggioni AP.Current presentation and management of heart failure in cardiology and internal medicine hospital units: a tale of two worlds--the TEMISTOCLE study.Am Heart J2003;146:735

[38] Miró Ò,Martín-Sánchez FJ.Research Group on Acute Heart Failure of the Spanish Society of Emergency Medicine (ICA-SEMES Research Group) ResearchersShort-term outcomes of heart failure patients with reduced and preserved ejection fraction after acute decompensation according to the final destination after emergency department care.Clin Res Cardiol2018;107:698-710

[39] Jong P,Liu PP,Lee DS.Care and outcomes of patients newly hospitalized for heart failure in the community treated by cardiologists compared with other specialists.Circulation2003;108:184-91

[40] Uthamalingam S,Selvaraj V.Outcomes of patients with acute decompensated heart failure managed by cardiologists versus noncardiologists.Am J Cardiol2015;115:466-71

[41] Selim AM,Iqbal M,Negassa A.Mortality and readmission rates in patients hospitalized for acute decompensated heart failure: a comparison between cardiology and general-medicine service outcomes in an underserved population.Clin Cardiol2015;38:131-8 PMCID:PMC6711015

[42] Ricciardi E,Guglielmi G.Characteristics of current heart failure patients admitted to internal medicine vs. cardiology hospital units: the VASCO study.Intern Emerg Med2020;15:1219-29

[43] Owan TE,Herges RM,Roger VL.Trends in prevalence and outcome of heart failure with preserved ejection fraction.N Engl J Med2006;355:251-9

[44] Ponikowski P,Anker SD.ESC Scientific Document Group2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.Eur Heart J2016;37:2129-200

[45] Anker SD,Filippatos G.EMPEROR-Preserved Trial InvestigatorsEmpagliflozin in heart failure with a preserved ejection fraction.N Engl J Med2021;385:1451-61

[46] Oghina S,Bézard M.The impact of patients with cardiac amyloidosis in HFpEF trials.JACC Heart Fail2021;9:169-78

[47] d’Arcy JL,Loudon MA.Large-scale community echocardiographic screening reveals a major burden of undiagnosed valvular heart disease in older people: the OxVALVE Population Cohort Study.Eur Heart J2016;37:3515-22 PMCID:PMC5216199

[48] Lüscher TF.Aortic stenosis: expanding treatment options.Eur Heart J2016;37:3483-5

[49] Mack MJ,Thourani VH.PARTNER 3 InvestigatorsTranscatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients.N Engl J Med2019;380:1695-705

[50] Griffin JM.Cardiac amyloidosis in severe aortic stenosis: we can find it but what should we do?.Eur J Heart Fail2020;22:1863-5

[51] Cecchi F,Betocchi S.The Italian Registry for hypertrophic cardiomyopathy: a nationwide survey.Am Heart J2005;150:947-54

[52] Maron MS,Lucove JC,Olivotto I.Occurrence of clinically diagnosed hypertrophic cardiomyopathy in the United States.Am J Cardiol2016;117:1651-4

[53] Canepa M,Tini C.Temporal trend in age at diagnosis of hypertrophic cardiomyopathy: an analysis of the share registry.Circulation2019;140:A16286

[54] Martinez-Naharro A,Abdel-Gadir A.Magnetic resonance in transthyretin cardiac amyloidosis.J Am Coll Cardiol2017;70:466-77

[55] Philippakis AA.Cardiac amyloidosis mimicking hypertrophic cardiomyopathy with obstruction: treatment with disopyramide.Circulation2012;125:1821-4

[56] Mookadam F,Olson LJ,Mookadam M.Dynamic left ventricular outflow tract obstruction in senile cardiac amyloidosis.Eur J Echocardiogr2006;7:465-8

[57] Maron BJ,Haas TS,Garberich RF.Hypertrophic cardiomyopathy with longevity to 90 years or older.Am J Cardiol2012;109:1341-7

[58] Robins LN.The diagnostic screening procedure writer: a tool to develop individualized screening procedures.Med Care1987;25:S106-22

[59] Alexander KM.Management of cardiac amyloidosis: do’s and don’ts.Can J Cardiol2020;36:444-6

[60] Hanna M,Maurer MS.Cardiac scintigraphy with technetium-99m-labeled bone-seeking tracers for suspected amyloidosis: JACC review topic of the week.J Am Coll Cardiol2020;75:2851-62

[61] Poterucha TJ,Bokhari S.Diagnosing transthyretin cardiac amyloidosis by technetium Tc 99m pyrophosphate: a test in evolution.JACC Cardiovasc Imaging2021;14:1221-31 PMCID:PMC8113330

[62] Geller HI,Mirto TM.Prevalence of monoclonal gammopathy in wild-type transthyretin amyloidosis.Mayo Clin Proc2017;92:1800-5

[63] Abildgaard N,Møller HE.Immunoelectron microscopy and mass spectrometry for classification of amyloid deposits.Amyloid2020;27:59-66

[64] Perugini E,Salvi F.Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy.J Am Coll Cardiol2005;46:1076-84

[65] Hutt DF,Burniston M.Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid.Eur Heart J Cardiovasc Imaging2017;18:1344-50

[66] Castano A,Narotsky DL.Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: predicting survival for patients with ATTR cardiac amyloidosis.JAMA Cardiol2016;1:880-9

[67] Rapezzi C,Guidalotti PL.Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis.JACC Cardiovasc Imaging2011;4:659-70

[68] Cappelli F,Costanzo EN.Lung uptake during 99mTc-hydroxymethylene diphosphonate scintigraphy in patient with TTR cardiac amyloidosis: An underestimated phenomenon.Int J Cardiol2018;254:346-50

[69] Dorbala S,Bokhari S.ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging.J Nucl Cardiol2019;26:2065-123

[70] Masri A,Ahmad S.Efficient 1-hour technetium-99 m pyrophosphate imaging protocol for the diagnosis of transthyretin cardiac amyloidosis.Circ Cardiovasc Imaging2020;13:e010249 PMCID:PMC7032611

[71] Poterucha TJ,Ruberg FL.False positive 99mTc-pyrophosphate scanning leading to inappropriate tafamidis prescriptions.JACC Cardiovasc Imaging2021;14:2042-4

[72] Hussain M,Jaber W.Value of SPECT imaging in patients with TTR-amyloid: ratios are not enough.J Nucl Cardiol2021;28:747-9

[73] Musumeci MB,Russo D.Low sensitivity of bone scintigraphy in detecting Phe64Leu mutation-related transthyretin cardiac amyloidosis.JACC Cardiovasc Imaging2020;13:1314-21

[74] Hershberger RE,Ho CY.Genetic evaluation of cardiomyopathy-a heart failure Society of America Practice Guideline.J Card Fail2018;24:281-302

[75] Adams D,Hund E.European Network for TTR-FAP (ATTReuNET)First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy.Curr Opin Neurol2016;29 Suppl 1:S14-26 PMCID:PMC4739312

[76] Kazi DS,Baron SJ.Cost-effectiveness of tafamidis therapy for transthyretin amyloid cardiomyopathy.Circulation2020;141:1214-24 PMCID:PMC7156331

[77] Gurwitz JH.Tafamidis-a pricey therapy for a not-so-rare condition.JAMA Cardiol2020;5:247-8

[78] Psotka MA.Tafamidis should be accessible for all patients with transthyretin amyloid cardiomyopathy.JACC Heart Fail2021;9:124-6

[79] Masri A,Wong C.Initial experience prescribing commercial tafamidis, the most expensive cardiac medication in history.JAMA Cardiol2020;5:1066-7 PMCID:PMC7301295